-- Ace Therapeutics, a leading provider of preclinical contract research services for stroke drug development, is advancing the discovery and development of novel stroke therapeutics by offering scientifically rigorous and tailored preclinical solutions centered on custom stroke animal models for drug development. As a specialized stroke CRO, Ace Therapeutics leverages years of collective expertise in stroke pathophysiology and animal modeling to design and validate models that closely mimic human stroke conditions, addressing the critical unmet need for translatable preclinical tools in stroke research.
Stroke is a highly heterogeneous disease with complex pathological mechanisms, making it impossible to simulate all aspects of human stroke with a single animal model. Recognizing this challenge, Ace Therapeutics has developed a comprehensive portfolio of custom stroke animal models, covering both ischemic and hemorrhagic stroke—the two primary subtypes of stroke in humans. Ace Therapeutics' approach prioritizes selecting the most appropriate model for each client's specific research goals, with a focus on rodent models (mice, rats, and gerbils) and non-rodent models (rabbits, pigs, and non-human primates) available for studies requiring more complex behavioral and physiological assessments. This tiered model strategy aligns with translational step-wise experimental design principles, enabling seamless progression from early-stage mechanistic research in small animals to late-stage safety and efficacy testing in large animals.
Ace Therapeutics offers a full spectrum of ischemic stroke models, including global and focal cerebral ischemic models, constructed using validated techniques such as endovascular filament occlusion, transcranial electrocoagulation, photothrombosis, endothelin-1-induced vasoconstriction, and embolic occlusion. Each ischemic model is rigorously controlled by Ace Therapeutics' team of professional scientists to ensure reproducible infarct formation and scientific validity. For hemorrhagic stroke research, Ace Therapeutics has established stable and reliable autologous blood injection models and bacterial collagenase injection models, addressing the common challenges associated with acquiring and validating hemorrhagic stroke models for preclinical research. All models are developed and validated in accordance with strict scientific protocols, with a focus on mimicking key human stroke pathologies such as cerebral perfusion deficits, blood-brain barrier (BBB) disruption, reperfusion injury, and neuroinflammation.
As a comprehensive CRO, Ace Therapeutics goes beyond model development to provide a complete suite of outcome measures and functional assessment tools for evaluating stroke models, ensuring clients can comprehensively analyze cognitive, behavioral, and sensorimotor responses post-stroke. The company's translational endpoints include standardized neurological scoring, advanced gait analysis, behavioral testing, and multimodal imaging—such as diffusion-weighted MRI (DWI) for early ischemic injury and edema quantification, gadolinium-enhanced MRI for BBB integrity assessment, and functional ultrasound imaging for in vivo visualization of cerebral blood vessels and vascular remodeling. For mechanistic studies, Ace Therapeutics offers ex vivo analyses including immunohistochemistry (IHC), protein quantification, and histological assessment of key biomarkers (e.g., claudin-5, occludin, ZO-1 for tight junction integrity; IgG/albumin for BBB leakage), supporting the evaluation of neuroinflammation, neuronal injury, and gliosis—critical for understanding drug mechanism of action (MoA).
About the company: Ace Therapeutics provides comprehensive contract research services for stroke drug discovery and development. With a team of experts having extensive experience in stroke research and animal modeling, Ace Therapeutics partners with biopharmaceutical companies, academic institutions, and research organizations worldwide to address the most pressing challenges in stroke drug development, providing scientifically rigorous and translatable preclinical solutions that accelerate the path to new life-saving stroke treatments.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/stroke/
Release ID: 89184424
Google
RSS